Drug targeting systems for inflammatory disease: One for all, all for one

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 225-234

  Crielaard, Bart J ^a   Lammers, Twan ^b,c   Schiffelers, Raymond M ^a,d   Storm, Gert ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF TWENTE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Drug targeting; Inflammatory disease; Multiple sclerosis; Nanomedicine; Rheumatoid arthritis

Indexed keywords

ACTIVE TARGETING; ATTRACTIVE STRATEGIES; CHRONIC INFLAMMATORY DISEASE; CURRENT STATUS; DISEASED TISSUES; DRUG TARGETING SYSTEMS; DRUG-TARGETING; INFLAMMATORY DISEASE; KEY ELEMENTS; MICROENVIRONMENTS; MULTIPLE SCLEROSIS; RHEUMATOID ARTHRITIS; STRATEGIC PRINCIPLES; STRUCTURAL CHANGE; TARGET TISSUES; THERAPEUTIC AGENTS; TUMOR TARGETING;

HISTOLOGY; MEDICAL NANOTECHNOLOGY; TISSUE;

DISEASES;

BETAMETHASONE SODIUM PHOSPHATE; CELECOXIB; CYCLODEXTRIN; DEXAMETHASONE SODIUM PHOSPHATE; DRUG CARRIER; EVANS BLUE; GLUCOCORTICOID; IBUPROFEN; INDOMETACIN; MATRIX METALLOPROTEINASE; METHOTREXATE; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMETHACRYLIC ACID DERIVATIVE; PREDNISOLONE 21 PHOSPHATE; SERUM ALBUMIN; ZINOSTATIN;

ANALGESIC ACTIVITY; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICULAR CARTILAGE; BLADDER DYSFUNCTION; BLOOD BRAIN BARRIER; DIPLOPIA; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG RESEARCH; DRUG TARGETING; ENTERITIS; FATIGUE; GENETIC PREDISPOSITION; HUMAN; HYPOALBUMINEMIA; IN VIVO STUDY; INFLAMMATORY DISEASE; JOINT DESTRUCTION; LOW DRUG DOSE; LYMPHATIC DRAINAGE; MICROGLIA; MOLECULAR SIZE; MULTIPLE SCLEROSIS; NONHUMAN; PAW EDEMA; PLASMA CLEARANCE; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RETICULOENDOTHELIAL SYSTEM; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; TARGET ORGAN; VISUAL IMPAIRMENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MULTIPLE SCLEROSIS;

EID: 84862659359     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.12.014     Document Type: Review

References (145)

1. R. Duncan, Polymer therapeutics as nanomedicines: new perspectives, Curr. Opin. Biotechnol. 22 (4) (2011) 492-501.
2. V.P. Torchilin, Drug Deliv., Vol. 197, Springer Berlin Heidelberg, 2010, pp. 3-53.
3. R. Duncan, Polymer conjugates as anticancer nanomedicines, Nat. Rev. Cancer 6 (9) (2006) 688-701.
4. T. Lammers, W.E. Hennink, G. Storm, Tumour-targeted nanomedicines: principles and practice, Br. J. Cancer 99 (3) (2008) 392-397.
5. F. Danhier, O. Feron, V. Préat, To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J. Control. Release 148 (2) (2010) 135-146.
6. E. Yelin, L. Murphy, M.G. Cisternas, A.J. Foreman, D.J. Pasta, C.G. Helmick, Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997, Arthritis Rheum. 56 (5) (2007) 1397-1407.
7. T. Kirchhoff, J. Ruof, T. Mittendorf, M. Rihl, M. Bernateck, W. Mau, H. Zeidler, R.E. Schmidt, S. Merkesdal, Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings, Rheumatology 50 (4) (2011) 756-761.
8. P. Rieckmann, Socio-economic aspects of neuroimmunological diseases, J. Neurol. 253 (Suppl. 5) (2006) V87-V90.
9. M. Coimbra, S.A. Kuijpers, S.P. van Seters, G. Storm, R.M. Schiffelers, Targeted delivery of anti-inflammatory agents to tumors, Curr. Pharm. Des. 15 (16) (2009) 1825-1843.
10. K.J. O'Byrne, A.G. Dalgleish, Chronic immune activation and inflammation as the cause of malignancy, Br. J. Cancer 85 (4) (2001) 473-483.
11. R.M. Schiffelers, M. Banciu, J.M. Metselaar, G. Storm, Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer, J. Liposome Res. 16 (3) (2006) 185-194.
12. Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res. 46 (12 I) (1986) 6387-6392.
13. H. Maeda, M. Ueda, T. Morinaga, T. Matsumoto, Conjugation of poly(styrene-comaleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties, J. Med. Chem. 28 (4) (1985) 455-461.
14. J. Fang, H. Nakamura, H. Maeda, The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect, Adv. Drug Deliv. Rev. 63 (3) (2011) 136-151.
15. H. Maeda, Y. Matsumura, EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy, Adv. Drug Deliv. Rev. 63 (3) (2011) 129-130.
16. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release 65 (1-2) (2000) 271-284.
17. M. Talelli, C.J.F. Rijcken, C.F. van Nostrum, G. Storm, W.E. Hennink, Micelles based on HPMA copolymers, Adv. Drug Deliv. Rev. 62 (2) (2010) 231-239.
18. T. Lammers, Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations, Adv. Drug Deliv. Rev. 62 (2) (2010) 203-230.
19. I. Kushner, J.A. Somerville, Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation, Arthritis Rheum. 14 (5) (1971) 560-570.
20. J.R. Levick, Permeability of rheumatoid and normal human synovium to specific plasma proteins, Arthritis Rheum. 24 (12) (1981) 1550-1560.
21. C. Gómez-Vaquero, J.M. Nolla, J. Fiter, J.M. Ramon, R. Concustell, J. Valverde, D. Roig-Escofet, Nutritional status in patients with rheumatoid arthritis, Joint Bone Spine 68 (5) (2001) 403-409.
22. F.C. Ballantyne, A. Fleck, W.C. Dick, Albumin metabolism in rheumatoid arthritis, Ann. Rheum. Dis. 30 (3) (1971) 265-270.
23. J. Bennett, J. Basivireddy, A. Kollar, K.E. Biron, P. Reickmann, W.A. Jefferies, S. McQuaid, Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE, J. Neuroimmunol. 229 (1-2) (2010) 180-191.
24. J. Kirk, J. Plumb, M. Mirakhur, S. McQuaid, Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination, J. Pathol. 201 (2) (2003) 319-327.
25. E.E. Kwon, J.W. Prineas, Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study, J. Neuropathol. Exp. Neurol. 53 (6) (1994) 625-636.
26. H. Maeda, Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects, Bioconjug. Chem. 21 (5) (2010) 797-802.
27. P. Calvo, B. Gouritin, H. Villarroya, F. Eclancher, C. Giannavola, C. Klein, J.P. Andreux, P. Couvreur, Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat, Eur. J. Neurosci. 15 (8) (2002) 1317-1326.
28. J. Schmidt, J.M. Metselaar, M.H.M.Wauben, K.V. Toyka, G. Storm, R. Gold, Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis, Brain 126 (8) (2003) 1895-1904.
29. A. Wunder, U. Müller-Ladner, E.H.K. Stelzer, J.r. Funk, E. Neumann, G. Stehle, T. Pap, H.r. Sinn, S. Gay, C. Fiehn, Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis, J. Immunol. 170 (9) (2003) 4793-4801.
30. D. Wang, S. Miller, X.-M. Liu, B. Anderson, X.S. Wang, S. Goldring, Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis, Arthritis Res. Ther. 9 (1) (2007) R2.
31. J.M. Metselaar, M.H.M. Wauben, J.P.A. Wagenaar-Hilbers, O.C. Boerman, G. Storm, Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes, Arthritis Rheum. 48 (7) (2003) 2059-2066.
32. S.M. Grayson, W.T. Godbey, The role of macromolecular architecture in passively targeted polymeric carriers for drug and gene delivery, J. Drug Target. 16 (5) (2008) 329-356.
33. E.A. Simone, T.D. Dziubla, V.R. Muzykantov, Polymeric carriers: role of geometry in drug delivery, Expert Opin. Drug Deliv. 5 (12) (2008) 1283-1300.
34. E.R. Gillies, E. Dy, J.M.J. Fréchet, F.C. Szoka, Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture, Mol. Pharm. 2 (2) (2005) 129-138.
35. T. Yamaoka, Y. Tabata, Y. Ikada, Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice, J. Pharm. Sci. 83 (4) (1994) 601-606.
36. Y.H. Bae, K. Park, Targeted drug delivery to tumors: myths, reality and possibility, J. Control. Release 153 (3) (2011) 198-205.
37. P. Ruenraroengsak, J.M. Cook, A.T. Florence, Nanosystem drug targeting: facing up to complex realities, J. Control. Release 141 (3) (2010) 265-276.
38. T.M. Allen, L. Murray, S. MacKeigan, M. Shah, Chronic liposome administration in mice: effects on reticuloendothelial function and tissue distribution, J. Pharmacol. Exp. Ther. 229 (1) (1984) 267-275.
39. E. Kluza, S.Y. Yeo, S. Schmid, D.W. van der Schaft, R.W. Boekhoven, R.M. Schiffelers, G. Storm, G.J. Strijkers, K. Nicolay, Anti-tumor activity of liposomal glucocorticoids: the relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity, J. Control. Release 151 (1) (2011) 10-17.
40. C. Costa, J. Incio, R. Soares, Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10 (3) (2007) 149-166.
41. Z. Szekanecz, T. Besenyei, Á. Szentpétery, A.E. Koch, Angiogenesis and vasculogenesis in rheumatoid arthritis, Curr. Opin. Rheumatol. 22 (3) (2010) 299-306.
42. A. Koch, O. Distler, Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis, Arthritis Res. Ther. 9 (Suppl 2) (2007) S3.
43. A. Luttun, M. Tjwa, L. Moons, Y. Wu, A. Angelillo-Scherrer, F. Liao, J.A. Nagy, A. Hooper, J. Priller, B. De Klerck, V. Compernolle, E. Daci, P. Bohlen, M. Dewerchin, J.-M. Herbert, R. Fava, P. Matthys, G. Carmeliet, D. Collen, H.F. Dvorak, D.J. Hicklin, P. Carmeliet, Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1, Nat. Med. 8 (8) (2002) 831-840.
44. T.J. Seabrook, A. Littlewood-Evans, V. Brinkmann, B. Pöllinger, C. Schnell, P.C. Hiestand, Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions, J. Neuroinflammation 7 (2010).
45. J.E. Holley, J. Newcombe, J.L. Whatmore, N.J. Gutowski, Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter, Neurosci. Lett. 470 (1) (2010) 65-70.
46. D.J. Veale, U. Fearon, Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting, Best Pract. Res. Clin. Rheumatol. 20 (5) (2006) 941-947.
47. Z. Szekanecz, A.E. Koch, Angiogenesis and its targeting in rheumatoid arthritis, Vascul. Pharmacol. 51 (1) (2009) 1-7.
48. S.A. Yoo, S.K. Kwok, W.U. Kim, Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention, Mediators Inflamm. 2008 (2008) 129873.
49. C.-S. Zhu, X.-Q. Hu, Z.-J. Xiong, Z.-Q. Lu, G.-Y. Zhou, D.-J. Wang, Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) inhibits experimental autoimmune encephalomyelitis in dark Agouti (DA) rats, Life Sci. 83 (11-12) (2008) 404-412.
50. R.W. Kinne, B. Stuhlmüller, G.R. Burmester, Cells of the synovium in rheumatoid arthritis. Macrophages, Arthritis Res. Ther. 9 (6) (2007).
51. R.A. Reilkoff, R. Bucala, E.L. Herzog, Fibrocytes: emerging effector cells in chronic inflammation, Nat. Rev. Immunol. 11 (6) (2011) 427-435.
52. H. Li, M.L. Cuzner, J. Newcombe, Microglia-derived macrophages in early multiple sclerosis plaques, Neuropathol. Appl. Neurobiol. 22 (3) (1996) 207-215.
53. M.A. Proescholdt, S. Jacobson, N. Tresser, E.H. Oldfield, M.J. Merrill, Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats, J. Neuropathol. Exp. Neurol. 61 (10) (2002) 914-925.
54. R.A. Fava, N.J. Olsen, G. Spencer-Green, K.T. Yeo, T.K. Yeo, B. Berse, R.W. Jackman, D.R. Senger, H.F. Dvorak, L.F. Brown, Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue, J. Exp. Med. 180 (1) (1994) 341-346.
55. D. Cox, M. Brennan, N. Moran, Integrins as therapeutic targets: lessons and opportunities, Nat. Rev. Drug Discov. 9 (10) (2010) 804-820.
56. D. Gerlag, E. Borges, P. Tak, H.M. Ellerby, D. Bredesen, R. Pasqualini, E. Ruoslahti, G. Firestein, Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature, Arthritis Res. 3 (6) (2001) 357-361.
57. P.S. Low, W.A. Henne, D.D. Doorneweerd, Discovery and development of folicacid- based receptor targeting for imaging and therapy of cancer and inflammatory diseases, Acc. Chem. Res. 41 (1) (2008) 120-129.
58. G.A. Koning, R.M. Schiffelers, M.H.M. Wauben, R.J. Kok, E. Mastrobattista, G. Molema, T.L.M. ten Hagen, G. Storm, Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis, Arthritis Rheum. 54 (4) (2006) 1198-1208.
59. C.P. Leamon, P.S. Low, Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis, Proc. Natl. Acad. Sci. U. S. A. 88 (13) (1991) 5572-5576.
60. S.D. Weitman, R.H. Lark, L.R. Coney, D.W. Fort, V. Frasca, V.R. Zurawski Jr., B.A. Kamen, Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues, Cancer Res. 52 (12) (1992) 3396-3401.
61. 2 and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis, Arthritis Rheum. 42 (8) (1999) 1609-1616.
62. M.J. Turk, G.J. Breur, W.R. Widmer, C.M. Paulos, L.C. Xu, L.A. Grote, P.S. Low, Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis, Arthritis Rheum. 46 (7) (2002) 1947-1955.
63. P.S. Low, A.C. Antony, Folate receptor-targeted drugs for cancer and inflammatory diseases, Adv. Drug Deliv. Rev. 56 (8) (2004) 1055-1058.
64. W. Xia, A.R. Hilgenbrink, E.L. Matteson, M.B. Lockwood, J.X. Cheng, P.S. Low, A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages, Blood 113 (2) (2009) 438-446.
65. M.D. Salazar, M. Ratnam, The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 26 (1) (2007) 141-152.
66. X. Wang, F. Shen, J.H. Freisheim, L.E. Gentry, M. Ratnam, Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates, Biochem. Pharmacol. 44 (9) (1992) 1898-1901.
67. H. Elnakat, M. Ratnam, Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy, Adv. Drug Deliv. Rev. 56 (8) (2004) 1067-1084.
68. J.F. Kukowska-Latallo, K.A. Candido, Z. Cao, S.S. Nigavekar, I.J. Majoros, T.P. Thomas, L.P. Balogh, M.K. Khan, J.R. Baker Jr., Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer, Cancer Res. 65 (12) (2005) 5317-5324.
69. X. Zhao, H. Li, R.J. Lee, Targeted drug delivery via folate receptors, Expert Opin. Drug Deliv. 5 (3) (2008) 309-319.
70. M.J. Turk, D.J. Waters, P.S. Low, Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma, Cancer Lett. 213 (2) (2004) 165-172.
71. P.C. Brooks, R.A.F. Clark, D.A. Cheresh, Requirement of vascular integrin αvβ3 for angiogenesis, Science 264 (5158) (1994) 569-571.
72. C.M. Storgard, D.G. Stupack, A. Jonczyk, S.L. Goodman, R.I. Fox, D.A. Cheresh, Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist, J. Clin. Invest. 103 (1) (1999) 47-54.
73. P.C. Brooks, A.M.P. Montgomery, M. Rosenfeld, R.A. Reisfeld, T. Hu, G. Klier, D.A. Cheresh, Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, Cell 79 (7) (1994) 1157-1164.
74. Y. Takada, Y. Ono, J. Sagusa, C. Mitsiades, N. Mitsiades, J. Tsai, Y. He, E. Maningding, A. Coleman, D. Ramirez-Maverakis, R. Rodriquez, E. Maverakis, A T cell-binding fragment of fibrinogen can prevent autoimmunity, J. Autoimmun. 34 (4) (2010) 453-459.
75. H.F. Zhou, H.W. Chan, S.A. Wickline, G.M. Lanza, C.T.N. Pham, αvβ3-Targeted nanotherapy suppresses inflammatory arthritis in mice, FASEB J. 23 (9) (2009) 2978-2985.
76. N. Nasongkla, X. Shuai, H. Ai, B.D. Weinberg, J. Pink, D.A. Boothman, J. Gao, cRGD-functionalized polymer micelles for targeted doxorubicin delivery, Angew. Chem. 43 (46) (2004) 6323-6327.
77. L. Klareskog, A.I. Catrina, S. Paget, Rheumatoid arthritis, Lancet 373 (9664) (2009) 659-672.
78. E. Karouzakis, M. Neidhart, R.E. Gay, S. Gay, Molecular and cellular basis of rheumatoid joint destruction, Immunol. Lett. 106 (1) (2006) 8-13.
79. H. Takayanagi, H. Iizuka, T. Juji, T. Nakagawa, A. Yamamoto, T. Miyazaki, Y. Koshihara, H. Oda, K. Nakamura, S. Tanaka, Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis, Arthritis Rheum. 43 (2) (2000) 259-269.
80. G.S. Firestein, Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum. 39 (11) (1996) 1781-1790.
81. S. Lefèvre, A. Knedla, C. Tennie, A. Kampmann, C. Wunrau, R. Dinser, A. Korb, E.M. Schnäker, I.H. Tarner, P.D. Robbins, C.H. Evans, H. Stürz, J. Steinmeyer, S. Gay, J. Schölmerich, T. Pap, U. Müller-Ladner, E. Neumann, Synovial fibroblasts spread rheumatoid arthritis to unaffected joints, Nat. Med. 15 (12) (2009) 1414-1420.
82. T.K. Kvien, Epidemiology and Burden of Illness of Rheumatoid Arthritis, Pharmacoeconomics 22 (2 Suppl.) (2004) 1-12.
83. F. Wolfe, D.M. Mitchell, J.T. Sibley, J.F. Fries, D.A. Bloch, C.A. Williams, P.W. Spitz, M. Haga, S.M. Kleinheksel, M.A. Cathey, The mortality of rheumatoid arthritis, Arthritis Rheum. 37 (4) (1994) 481-494.
84. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, R.I. Fox, C.G. Jackson, M. Lange, D.J. Burge, A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, N. Engl. J. Med. 340 (4) (1999) 253-259.
85. P. Barrera, A. Blom, P.L.E.M. van Lent, L. van Bloois, J.H. Beijnen, N. van Rooijen, M.C. de Waal Malefijt, L.B.A. van de Putte, G. Storm, W.B. van den Berg, Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis, Arthritis Rheum. 43 (9) (2000) 1951-1959.
86. N. van Rooijen, E. van Kesteren-Hendrikx, Clodronate liposomes: perspectives in research and therapeutics, J. Liposome Res. 12 (1-2) (2002) 81-94.
87. P.L. van Lent, A.E. Holthuysen, N. van Rooijen, L.B. van de Putte, W.B. van den Berg, Local removal of phagocytic synovial lining cells by clodronateliposomes decreases cartilage destruction during collagen type II arthritis, Ann. Rheum. Dis. 57 (7) (1998) 408-413.
88. P.J. Richards, A.S. Williams, R.M. Goodfellow, B.D. Williams, Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis, Rheumatology 38 (9) (1999) 818-825.
89. R. Anderson, A. Franch, M. Castell, F.J. Perez-Cano, R. Bräuer, D. Pohlers, M. Gajda, A.P. Siskos, T. Katsila, C. Tamvakopoulos, U. Rauchhaus, S. Panzner, R.W. Kinne, Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis, Arthritis Res. Ther. 12 (4) (2010).
90. U. Rauchhaus, F.W. Schwaiger, S. Panzner, Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment, Arthritis Res. Ther. 11 (6) (2009).
91. J.M. van den Hoven, W. Hofkens, M.H.M. Wauben, J.P.A. Wagenaar-Hilbers, J.H. Beijnen, B. Nuijen, J.M. Metselaar, G. Storm, Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis, Int. J. Pharm. 16 (2) (2011) 471-477.
92. Y. Avnir, R. Ulmansky, V. Wasserman, S. Even-Chen, M. Broyer, Y. Barenholz, Y. Naparstek, Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis, Arthritis Rheum. 58 (1) (2008) 119-129.
93. T. Harigai, H. Hagiwara, Y. Ogawa, T. Ishizuka, S. Kaneda, J. Kimura, Prednisolone phosphate-containing TRX-20 liposomes inhibit cytokine and chemokine production in human fibroblast-like synovial cells: a novel approach to rheumatoid arthritis therapy, J. Pharm. Pharmacol. 59 (1) (2007) 137-143.
94. J.M. Metselaar, W.B. van den Berg, A.E.M. Holthuysen, M.H.M. Wauben, G. Storm, P.L.E.M. van Lent, Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis, Ann. Rheum. Dis. 63 (4) (2004) 348-353.
95. D. Wang, S.C. Miller, M. Sima, D. Parker, H. Buswell, K.C. Goodrich, P. Kopečková, J. Kopeček, The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study, Pharm. Res. 21 (10) (2004) 1741-1749.
96. X.-M. Liu, L.-D. Quan, J. Tian, Y. Alnouti, K. Fu, G. Thiele, D. Wang, Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis, Pharm. Res. 25 (12) (2008) 2910-2919.
97. L.-D. Quan, P.E. Purdue, X.-M. Liu, M. Boska, S. Lele, G. Thiele, T. Mikuls, H. Dou, S. Goldring, D. Wang, Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy, Arthritis Res. Ther. 12 (5) (2010) R170.
98. X.-M. Liu, L.-d. Quan, J. Tian, F.C. Laquer, P. Ciborowski, D. Wang, Syntheses of click PEG-dexamethasone conjugates for the treatment of rheumatoid arthritis, Biomacromolecules 11 (10) (2010) 2621-2628.
99. D. Funk, H.H. Schrenk, E. Frei, Development of a novel polyethylene glycolcorticosteroid-conjugate with an acid-cleavable linker, J. Drug Target. 19 (6) (2011) 434-445.
100. J. Hwang, K. Rodgers, J.C. Oliver, T. Schluep, α-Methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy, Int. J. Nanomedicine 3 (3) (2008) 359-371.
101. M. Higaki, T. Ishihara, N. Izumo, M. Takatsu, Y. Mizushima, Treatment of experimental arthritis with poly(D, L-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate, Ann. Rheum. Dis. 64 (8) (2005) 1132-1136.
102. T. Ishihara, T. Kubota, T. Choi, M. Higaki, Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate, J. Pharmacol. Exp. Ther. 329 (2) (2009) 412-417.
103. T. Ishihara, M. Takahashi, M. Higaki, Y. Mizushima, T. Mizushima, Preparation and characterization of a nanoparticulate formulation composed of PEG-PLA and PLA as anti-inflammatory agents, Int. J. Pharm. 385 (1-2) (2010) 170-175.
104. M.M. Tielemans, T. Eikendal, J.B.M.J. Jansen, M.G.H. van Oijen, Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements, Drug Saf. 33 (6) (2010) 443-453.
105. P. Srinath, S.P. Vyas, P.V. Diwan, Preparation and pharmacodynamic evaluation of liposomes of indomethacin, Drug Dev. Ind. Pharm. 26 (3) (2000) 313-321.
106. S. Palakurthi, S.P. Vyas, P.V. Diwan, Biodisposition of PEG-coated lipid microspheres of indomethacin in arthritic rats, Int. J. Pharm. 290 (1-2) (2005) 55-62.
107. A.S. Chauhan, N.K. Jain, P.V. Diwan, A.J. Khopade, Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats, J. Drug Target. 12 (9-10) (2004) 575-583.
108. D. Chandrasekar, R. Sistla, F.J. Ahmad, R.K. Khar, P.V. Diwan, Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery, J. Biomed. Mater. Res. A 82A (1) (2007) 92-103.
109. D. Chandrasekar, R. Sistla, F.J. Ahmad, R.K. Khar, P.V. Diwan, The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats, Biomaterials 28 (3) (2007) 504-512.
110. A.S. Chauhan, P.V. Diwan, N.K. Jain, D.A. Tomalia, Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly (amidoamine) dendrimers, Biomacromolecules 10 (5) (2009) 1195-1202.
111. P.A. Liso, M. Rebuelta, J.S. Román, A. Gallardo, A.M. Villar, Polymeric drugs derived from Ibuprofen with improved antiinflammatory profile, J. Biomed. Mater. Res. 32 (4) (1996) 553-560.
112. H. Thakkar, R.K. Sharma, A.K. Mishra, K. Chuttani, R.R. Murthy, Albumin microspheres as carriers for the antiarthritic drug celecoxib, AAPS PharmSciTech 6 (1) (2004) E65-E73.
113. A. Williams, R. Goodfellow, N. Topley, N. Amos, B. Williams, The suppression of rat collagen-induced arthritis and inhibition of macrophage derived mediator release by liposomal methotrexate formulations, Inflamm. Res. 49 (4) (2000) 155-161.
114. A.S. Williams, S.G. Jones, R.M. Goodfellow, N. Amos, B.D. Williams, Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis, Br. J. Pharmacol. 128 (1) (1999) 234-240.
115. A. Wunder, U. Müller-Ladner, E.H.K. Stelzer, J. Funk, E. Neumann, G. Stehle, T. Pap, H. Sinn, S. Gay, C. Fiehn, Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis, J. Immunol. 170 (9) (2003) 4793-4801.
116. C. Fiehn, U. Müller-Ladner, S. Gay, S. Krienke, S. Freudenberg-Konrad, J. Funk, A.D. Ho, H. Sinn, A. Wunder, Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX, Rheumatology 43 (9) (2004) 1097-1105.
117. C. Fiehn, F. Kratz, G. Sass, U. Müller-Ladner, E. Neumann, Targeted drug delivery by in vivo coupling to endogenous albumin: An albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis, Ann. Rheum. Dis. 67 (8) (2008) 1188-1191.
118. B.M. Keegan, J.H. Noseworthy, Multiple Sclerosis, Annu. Rev. Med. 53 (1) (2002) 285-302.
119. C. Stadelmann, Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications, Curr. Opin. Neurol. 24 (3) (2011) 224-229.
120. A. Bitsch, J. Schuchardt, S. Bunkowski, T. Kuhlmann, W. Brück, Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation, Brain 123 (6) (2000) 1174-1183.
121. R. Dutta, B.D. Trapp, Pathogenesis of axonal and neuronal damage in multiple sclerosis, Neurology 68 (22 Suppl. 3) (2007) S22-S31.
122. C. Stadelmann, C. Wegner, W. Brück, Inflammation, demyelination, and degeneration - Recent insights from MS pathology, BBA-Mol. Basis Dis. 1812 (2) (2011) 275-282.
123. L.M. Schönrock, G. Gawlowski, W. Brück, Interleukin-6 expression in human multiple sclerosis lesions, Neurosci. Lett. 294 (1) (2000) 45-48.
124. A.R. Calabria, E.V. Shusta, Blood-brain barrier genomics and proteomics: elucidating phenotype, identifying disease targets and enabling brain drug delivery, Drug Discov. Today 11 (17-18) (2006) 792-799.
125. F. Brusaferri, L. Candelise, Steriods for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials, J. Neurol. 247 (6) (2000) 435-442.
126. J. Schmidt, J.M. Metselaar, R. Gold, Intravenous liposomal prednisolone downregulates in situ TNF-α production by T-cells in experimental autoimmune encephalomyelitis, J. Histochem. Cytochem. 51 (9) (2003) 1241-1244.
127. R.A. Linker, C. Weller, F. Lühder, A. Mohr, J. Schmidt, M. Knauth, J.M. Metselaar, R. Gold, Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: Long-term protective effects and enhanced efficacy of methylprednisolone formulations, Exp. Neurol. 211 (2) (2008) 397-406.
128. B.J. Crielaard, T. Lammers, M.E. Morgan, L. Chaabane, S. Carboni, B. Greco, P. Zaratin, A.D. Kraneveld, G. Storm, Macrophages and liposomes in inflammatory disease: friends or foes? Int. J. Pharm. 416 (2) (2011) 499-506.
129. W. Hu, J.M. Metselaar, L.-H. Ben, P.D. Cravens, M.P. Singh, E.M. Frohman, T.N. Eagar, M.K. Racke, B.C. Kieseier, O. Stüve, PEG minocycline-liposomes ameliorate CNS autoimmune disease, PLoS One 4 (1) (2009) e4151.
130. P. Kizelsztein, H. Ovadia, O. Garbuzenko, A. Sigal, Y. Barenholz, Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis, J. Neuroimmunol. 213 (1-2) (2009) 20-25.
131. T. Osanai, Y. Nagai, Suppression of experimental allergic encephalomyelitis (EAE) with liposome-encapsulated protease inhibitor: Therapy through the blood-brain barrier, Neurochem. Res. 9 (10) (1984) 1407-1416.
132. I. Huitinga, N. van Rooijen, C. de Groot, B. Uitdehaag, C. Dijkstra, Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages, J. Exp. Med. 172 (4) (1990) 1025-1033.
133. C.F. Brosnan, M.B. Bornstein, B.R. Bloom, The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis, J. Immunol. 126 (2) (1981) 614-620.
134. G. Cavaletti, A. Cassetti, A. Canta, S. Galbiati, A. Gilardini, N. Oggioni, V. Rodriguez-Menendez, A. Fasano, G.M. Liuzzi, U. Fattler, S. Ries, J. Nieland, P. Riccio, H. Haas, Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis, Mol. Pharm. 6 (5) (2009) 1363-1370.
135. V. Rousseau, B. Denizot, J.J. Le Jeune, P. Jallet, Early detection of liposome brain localization in rat experimental allergic encephalomyelitis, Exp. Brain Res. 125 (3) (1999) 255-264.
136. J.M. Boggs, A. Goundalkar, F. Doganoglu, N. Samji, J. Kurantsin-Mills, K.M. Koshy, Antigen-targeted liposome-encapsulated methotrexate specifically kills lymphocytes sensitized to the nonapeptide of myelin basic protein, J. Neuroimmunol. 17 (1) (1987) 35-48.
137. K. Avrilionis, J.M. Boggs, Suppression of experimental allergic encephalomyelitis by the encephalitogenic peptide, in solution or bound to liposomes, J. Neuroimmunol. 35 (1-3) (1991) 201-210.
138. J.R.F. Cummings, S. Keshav, S.P.L. Travis, Medical management of Crohn's disease, BMJ 336 (7652) (2008) 1062-1066.
139. V. Awasthi, B. Goins, L. McManus, R. Klipper, W.T. Phillips, [99mTc] liposomes for localizing experimental colitis in arabbit model, Nucl. Med. Biol. 30 (2) (2003) 159-168.
140. V.D. Awasthi, B. Goins, R. Klipper, W.T. Phillips, Accumulation of PEG-liposomes in the inflamed colon of rats: potential for therapeutic and diagnostic targeting of inflammatory bowel diseases, J. Drug Target. 10 (5) (2002) 419-427.
141. T. Aychek, K. Vandoorne, O. Brenner, S. Jung, M. Neeman, Quantitative analysis of intravenously administered contrast media reveals changes in vascular barrier functions in a murine colitis model, Magn. Reson. Med. 66 (1) (2011) 235-243.
142. B. Moulari, D. Pertuit, Y. Pellequer, A. Lamprecht, The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis, Biomaterials 29 (34) (2008) 4554-4560.
143. A. Makhlof, Y. Tozuka, H. Takeuchi, pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model, Eur. J. Pharm. Biopharm. 72 (1) (2009) 1-8.
144. A. Lamprecht, U. Schäfer, C.-M. Lehr, Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa, Pharm. Res. 18 (6) (2001) 788-793.
145. A. Lamprecht, N. Ubrich, H. Yamamoto, U. Schäfer, H. Takeuchi, P. Maincent, Y. Kawashima, C.-M. Lehr, Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease, J. Pharmacol. Exp. Ther. 299 (2) (2001) 775-781.